Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.

Bjelica B, Peric S, Gwathmey K, Sadjadi R, Bozovic I, Burns TM, Basta I.

J Peripher Nerv Syst. 2019 Jun 18. doi: 10.1111/jns.12329. [Epub ahead of print]

PMID:
31209940
2.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
3.

Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis.

Ramdharry G, Morrow J, Hudgens S, Skorupinska I, Gwathmey K, Currence M, Herbelin L, Jawdat O, Pasnoor M, Mcvey A, Barohn RJ, Burns TM, Dimachkie MM, Amato AA, Hanna MG, Machado PM.

Muscle Nerve. 2019 Aug;60(2):161-168. doi: 10.1002/mus.26521. Epub 2019 Jun 7.

PMID:
31107564
4.

Myasthenia gravis.

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM.

Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Review.

PMID:
31048702
5.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.

Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.

6.

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF Jr, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK.

Muscle Nerve. 2019 Apr;59(4):404-410. doi: 10.1002/mus.26404. Epub 2019 Jan 14.

PMID:
30575980
7.

Clinical outcome assessments: The "Rasch-Ionale" for improved accuracy.

Narayanaswami P, Burns TM.

Muscle Nerve. 2018 Sep;58(3):327-329. doi: 10.1002/mus.26155. Epub 2018 Jun 15. No abstract available.

PMID:
29742794
8.

Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI.

Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, Russell JW, Shaibani A, Mauermann ML, Hehir MK, Kolb N, Guptill J, Hobson-Webb L, Gable K, Raja S, Silvestri N, Wolfe GI, Smith AG, Malik R, Traub R, Joshi A, Elliott MP, Jones S, Burns TM.

Neurology. 2018 Jun 5;90(23):e2034-e2041. doi: 10.1212/WNL.0000000000005643. Epub 2018 May 4.

9.

Estimating and managing fatigue for our patients: Are we measuring up?

Burns TM.

Muscle Nerve. 2018 Aug;58(2):182-183. doi: 10.1002/mus.26125. Epub 2018 Apr 17. No abstract available.

PMID:
29534289
10.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
11.

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.

Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM.

Neurology. 2017 Sep 5;89(10):1069-1077. doi: 10.1212/WNL.0000000000004341. Epub 2017 Aug 11.

PMID:
28801338
12.

On being sick: Musings about kindness, side effects, and slowing down.

Burns TM.

Neurology. 2017 Aug 1;89(5):414-416. doi: 10.1212/WNL.0000000000004170. Epub 2017 Jun 23. No abstract available.

PMID:
28645912
13.

Analysis of Central and Peripheral Vision Reaction Times in Patients With Postconcussion Visual Dysfunction.

Clark JF, Ellis JK, Burns TM, Childress JM, Divine JG.

Clin J Sport Med. 2017 Sep;27(5):457-461. doi: 10.1097/JSM.0000000000000381.

PMID:
28107216
14.

Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16).

Ballow M, Conaway MR, Sriaroon P, Rachid RA, Seeborg FO, Duff CM, Bonilla FA, Younger MEM, Shapiro R, Burns TM.

J Allergy Clin Immunol. 2017 Jun;139(6):2007-2010.e8. doi: 10.1016/j.jaci.2016.11.029. Epub 2017 Jan 5. No abstract available.

PMID:
28065678
15.

Reply.

Burns TM, Smith GA.

Muscle Nerve. 2017 Jan;55(1):138-140. doi: 10.1002/mus.25436. Epub 2016 Nov 16. No abstract available.

PMID:
27756114
16.

Using disease-specific, patient-reported measures in everyday clinic.

Burns TM.

Neurology. 2016 Aug 30;87(9):858-9. doi: 10.1212/WNL.0000000000002972. Epub 2016 Jul 8. No abstract available.

PMID:
27402896
17.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

18.

SUNCT headaches after ipsilateral ophthalmic-distribution zoster.

Nagel MA, Burns TM, Gilden D.

J Neurol Sci. 2016 Jul 15;366:207-208. doi: 10.1016/j.jns.2016.05.027. Epub 2016 May 14.

19.

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.

Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M.

Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7.

PMID:
27220659
20.

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI.

Muscle Nerve. 2016 Feb;53(2):165-8. doi: 10.1002/mus.25009. Epub 2015 Dec 21. No abstract available.

PMID:
26662952
21.

Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument.

Gwathmey KG, Conaway MR, Sadjadi R, Joshi A, Barnett C, Bril V, Ng E, David W, Gable K, Guptill JT, Hobson-Webb LD, Dineen J, Hehir M, Brannagan TH 3rd, Byun E, Adler M, Burns TM.

Muscle Nerve. 2016 Jun;54(1):9-17. doi: 10.1002/mus.24985. Epub 2015 Dec 29.

22.

The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis.

Burns TM.

Muscle Nerve. 2016 Jan;53(1):3-4. doi: 10.1002/mus.24953. Epub 2015 Nov 26. No abstract available.

PMID:
26506220
23.

Myasthenia Gravis.

Gwathmey KG, Burns TM.

Semin Neurol. 2015 Aug;35(4):327-39. doi: 10.1055/s-0035-1558975. Epub 2015 Oct 6. Review.

PMID:
26502757
24.

Clinical profile of patients with myasthenia gravis followed at the University Hospital, Federal University of Minas Gerais.

Mourão AM, Barbosa LS, Comini-Frota ER, Freitas Dda S, Gomez RS, Burns TM, Lemos SM, Teixeira AL.

Rev Assoc Med Bras (1992). 2015 Mar-Apr;61(2):156-60. doi: 10.1590/1806-9282.61.02.156. Review.

25.

Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.

Hobson-Webb LD, Hehir M, Crum B, Visser A, Sanders D, Burns TM.

Muscle Nerve. 2015 Aug;52(2):211-5. doi: 10.1002/mus.24694. Epub 2015 Jun 18.

PMID:
25906756
26.

Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.

Burns TM, Sanders DB, Kaminski HJ, Wolfe GI, Narayanaswami P, Venitz J.

Muscle Nerve. 2015 May;51(5):635-7. doi: 10.1002/mus.24608. Epub 2015 Mar 31. No abstract available.

PMID:
25704880
27.

Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.

Sadjadi R, Reilly MM, Shy ME, Pareyson D, Laura M, Murphy S, Feely SM, Grider T, Bacon C, Piscosquito G, Calabrese D, Burns TM.

J Peripher Nerv Syst. 2014 Sep;19(3):192-6. doi: 10.1111/jns.12084.

28.

Reevaluating clinical measurement tools in therapeutic trials: time to make a Rasch decision?

Smith AG, Burns TM.

Neurology. 2014 Dec 2;83(23):2104-5. doi: 10.1212/WNL.0000000000001058. Epub 2014 Nov 5. No abstract available.

PMID:
25378676
29.

The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools.

Farrugia ME, Carmichael C, Cupka BJ, Warder J, Brennan KM, Burns TM.

Muscle Nerve. 2014 Oct;50(4):501-7. doi: 10.1002/mus.24214.

PMID:
24639179
30.

Ciprofloxacin enhances stress erythropoiesis in spleen and increases survival after whole-body irradiation combined with skin-wound trauma.

Fukumoto R, Burns TM, Kiang JG.

PLoS One. 2014 Feb 28;9(2):e90448. doi: 10.1371/journal.pone.0090448. eCollection 2014.

31.

Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items".

Mourão AM, Araújo CM, Barbosa LS, Gomez RS, Burns TM, Lemos SM, Teixeira AL.

Arq Neuropsiquiatr. 2013 Dec;71(12):955-8. doi: 10.1590/0004-282X20130180.

32.

Vasculitic neuropathies.

Gwathmey KG, Burns TM, Collins MP, Dyck PJ.

Lancet Neurol. 2014 Jan;13(1):67-82. doi: 10.1016/S1474-4422(13)70236-9. Review.

PMID:
24331794
33.

Electrical impedance myography correlates with standard measures of ALS severity.

Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Benatar M, Sharma KR, Narayanaswami P, Raynor EM, Watson ML, Shefner JM.

Muscle Nerve. 2014 Mar;49(3):441-3. doi: 10.1002/mus.24128. Epub 2013 Dec 19.

PMID:
24273034
34.

Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?

Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L; Muscle Study Group.

Muscle Nerve. 2014 Apr;49(4):483-6. doi: 10.1002/mus.23944.

PMID:
23835683
35.

The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice.

Burns TM.

Ann N Y Acad Sci. 2012 Dec;1274:99-106. doi: 10.1111/j.1749-6632.2012.06812.x.

PMID:
23252903
36.

"Measure twice, cut once": improving diagnostic accuracy of skin biopsy.

Burns TM, Smith AG.

Neurology. 2012 Nov 27;79(22):2164-5. doi: 10.1212/WNL.0b013e31827597e2. Epub 2012 Oct 24. No abstract available.

PMID:
23100394
37.

Reply: To PMID 22581550.

Sanders DB, Benatar M, Burns TM, Cutter GR.

Muscle Nerve. 2013 Jan;47(1):145-6. doi: 10.1002/mus.23668. Epub 2012 Oct 5. No abstract available.

PMID:
23042161
38.

The Neurology® podcast: 2007-2012: can you hear me now?

Moriarity SA, Burns TM.

Neurology. 2012 Sep 4;79(10):956-7. doi: 10.1212/WNL.0b013e318268473a. No abstract available.

PMID:
22946112
39.

More than meets the eye: the benefits of listening closely to what our patients with myasthenia gravis are telling us.

Burns TM.

Muscle Nerve. 2012 Aug;46(2):153-4. doi: 10.1002/mus.23461. No abstract available.

PMID:
22806362
40.

Wound trauma alters ionizing radiation dose assessment.

Kiang JG, Garrison BR, Burns TM, Zhai M, Dews IC, Ney PH, Cary LH, Fukumoto R, Elliott TB, Ledney GD.

Cell Biosci. 2012 Jun 11;2(1):20. doi: 10.1186/2045-3701-2-20.

41.

Electrical impedance myography as a biomarker to assess ALS progression.

Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Clawson L, Benatar M, Usher S, Sharma KR, Gautam S, Narayanaswami P, Raynor EM, Watson ML, Shefner JM.

Amyotroph Lateral Scler. 2012 Sep;13(5):439-45. doi: 10.3109/17482968.2012.688837. Epub 2012 Jun 7.

42.

Quality of life and measures of quality of life in patients with neuromuscular disorders.

Burns TM, Graham CD, Rose MR, Simmons Z.

Muscle Nerve. 2012 Jul;46(1):9-25. doi: 10.1002/mus.23245. Epub 2012 May 29. Review.

PMID:
22644588
43.

Recommendations for myasthenia gravis clinical trials.

Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, Kaminski HJ, Mantegazza R, Meriggioli MN, Quan J, Wolfe GI; Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Muscle Nerve. 2012 Jun;45(6):909-17. doi: 10.1002/mus.23330.

PMID:
22581550
44.

Psychometric evaluation of the myasthenia gravis composite using Rasch analysis.

Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM; MG Composite MG-QOL15 Study Group.

Muscle Nerve. 2012 Jun;45(6):820-5. doi: 10.1002/mus.23260.

PMID:
22581534
45.

MG-ADL: still a relevant outcome measure.

Muppidi S, Wolfe GI, Conaway M, Burns TM; MG COMPOSITE AND MG-QOL15 STUDY GROUP.

Muscle Nerve. 2011 Nov;44(5):727-31. doi: 10.1002/mus.22140.

PMID:
22006686
46.

Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, Maragakis NJ, Benatar M, David WS, Sharma KR, Rutkove SB.

Neurology. 2011 Jul 19;77(3):235-41. doi: 10.1212/WNL.0b013e318225aabf. Epub 2011 Jun 15.

47.

The evaluation of polyneuropathies.

Burns TM, Mauermann ML.

Neurology. 2011 Feb 15;76(7 Suppl 2):S6-13. doi: 10.1212/WNL.0b013e31820c3622. No abstract available.

PMID:
21321354
48.

The Oculobulbar Facial Respiratory score is a tool to assess bulbar function in myasthenia gravis patients.

Farrugia ME, Harle HD, Carmichael C, Burns TM.

Muscle Nerve. 2011 Mar;43(3):329-34. doi: 10.1002/mus.21880. Epub 2011 Feb 8.

PMID:
21305562
49.

The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis.

Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB; MG Composite and MG-OL15 Study Group.

Muscle Nerve. 2011 Jan;43(1):14-8. doi: 10.1002/mus.21883.

PMID:
21082698
50.

Clinical applications of therapeutic apheresis.

Balogun RA, Kaplan A, Ward DM, Okafor C, Burns TM, Torloni AS, Macik BG, Abdel-Rahman EM.

J Clin Apher. 2010;25(5):250-64. doi: 10.1002/jca.20249. Review. No abstract available.

PMID:
20806279

Supplemental Content

Loading ...
Support Center